Insider Buys
This tool is in beta, validation in progress.
Score components and checks ✓/✗ are not accurate for every transaction yet.
Score components and checks ✓/✗ are not accurate for every transaction yet.
Risk Factors Update Summary
- At September 30, 2024, our accumulated deficit increased to $58.6 million from $52 million, raising concerns.
- If Nasdaq delists our common shares, market liquidity could decrease, adversely affecting our capital access.
- In June 2024, EB05 was selected for a BARDA-funded Phase 2 study, shifting our clinical focus.
- The Preferred Shares have a stated value of $10,000 each, with a 10% annual return, causing dilution.
- Our common shares are highly concentrated, with Dr. Nijhawan owning 19.99% and executives 23.9%, influencing corporate actions.
Full Text Changes in Most Recent 10-K
Intended use: review the highlighted statements. These are additions to the risk factors disclosure in the most recent 10-K filing compared to the previous 10-K filing. Deleted and moved text is less important and is shown for context.
To view the full company filings, click on the following link to be taken to the SEC EDGAR database landing page for the company: https://www.sec.gov/edgar/browse/?CIK=1540159&owner=exclude
This content requires a 'Free' membership to view. Please create one here.
This content requires a 'Free' membership to view. Please create one here.